Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun 19:11:3561-3571.
doi: 10.2147/OTT.S155541. eCollection 2018.

Clinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis

Chaojie Liang  1 , Jingyang Zhao  2 , Hua Ge  1 , Guangming Li  1 , Jixiang Wu  1
Affiliations

Clinicopathological and prognostic significance of FoxM1 in hepatocellular carcinoma patients: a meta-analysis

Chaojie Liang et al. Onco Targets Ther. .

Abstract

Background and aims: Recently, the abnormal expression of FoxM1 has been found in many malignant tumors. However, the clinicopathological and prognostic value of FoxM1 expression in hepatocellular carcinoma (HCC) patients remains controversial. We conducted a meta-analysis to establish the relationship between FoxM1 expression and the clinicopathological features and prognostic value in patients with HCC.

Methods: An electronic search for relevant articles was conducted according to a set of criteria in the PubMed, Cochrane Library, Web of Science, EMBASE, Chinese CNKI and Chinese WanFang databases. The correlation data between FoxM1 expression and clinicopathological features and survival outcomes were analyzed. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% CIs were calculated using STATA14.2.

Results: A total of 14 studies comprising of 2,036 patients were enrolled in this meta-analysis. The results showed that FoxM1 expression was related to the incidence, tumor size (>5 cm), vascular invasion, differentiation and TNM stage. Moreover, overexpression of FoxM1 indicated a poor 3- and 5-year overall survival rate (OS) and recurrence-free survival rate (disease-free survival rate).

Conclusion: Our meta-analysis indicated that FoxM1 expression was associated with incidence, tumor size (>5 cm), vascular invasion, differentiation and TNM stage. Accordingly, FoxM1 may be a reliable prognostic biomarker for patients with HCC. However, additional high-quality studies are still needed to further support these findings.

Keywords: FoxM1; clinicopathological feature; hepatocellular carcinoma; meta-analysis; prognosis.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of the study selection process.
Figure 2
Figure 2
Forest plot and funnel plots of the studies evaluating the relationship between FoxM1 expression and clinicopathological features. Notes: (A) expression; (B) gender. Weights are from random-effects analysis.
Figure 3
Figure 3
Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features. Notes: (A) HBsAg; (B) AFP.
Figure 3
Figure 3
Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features. Notes: (A) HBsAg; (B) AFP.
Figure 4
Figure 4
Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features. Notes: (A) Liver cirrhosis; (B) tumor size.
Figure 5
Figure 5
Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features. Notes: (A) Vascular invasion; (B) tumor number. Weights are from random-effects analysis.
Figure 6
Figure 6
Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and clinicopathological features. Notes: (A) Differentiation; (B) TNM stage.
Figure 7
Figure 7
Forest plot and funnel plots of studies evaluating the relationship between FOXM1 expression and prognosis. Notes: (A) 3-year overall survival; (B) 5-year overall survival.
Figure 8
Figure 8
Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and prognosis. Notes: (A) 3-year recurrence-free survival; (B) 5-year recurrence-free survival; (C) disease-free survival.
Figure 8
Figure 8
Forest plot and funnel plots of studies evaluating the relationship between FoxM1 expression and prognosis. Notes: (A) 3-year recurrence-free survival; (B) 5-year recurrence-free survival; (C) disease-free survival.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gong XL, Qin SK. Progress in systemic therapy of advanced hepatocel-lular carcinoma. World J Gastroenterol. 2016;22(29):6582–6594. - PMC - PubMed
    1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379(982):1245–1255. - PubMed
    1. Avila MA, Berasain C, Sangro B, Prieto J. New therapies for hepatocellular carcinoma. Oncogene. 2006;25(27):3866–3884. - PubMed
    1. Nishikawa H, Kimura T, Kita R, Osaki Y. Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer. 2013;4(8):635–643. - PMC - PubMed
    1. Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7(11):847–859. - PubMed

LinkOut - more resources